Search

everythinglearnresearchcommunity

for

Search:↓

FOXN1 gene variants cause low T cells and immune issues from birth.

FOXN1 gene mutations cause a rare, severe immune disease treatable with cell or tissue transplants.

New drugs targeting DNA enzymes show promise for cancer treatment but have side effects like immune system suppression and hair loss.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

Thymic transplantation normalized some T-cells but not others, maintaining immune function.

Patients with Shwachman-Diamond syndrome often get misdiagnosed due to a wide range of symptoms, including immune system problems and bone abnormalities.

Men are more likely to have severe respiratory viral infections like COVID-19 due to hormonal and genetic differences, while women generally have stronger immune responses.

Transplant success has improved with better immunosuppressive drugs and donor matching.

Minoxidil might cause blood vessel-related skin lesions when applied to the scalp.

Combination therapies work better than single treatments for atrophic acne scars.

Changing the environment around stem cells could help tissue repair, but it's hard to be precise and avoid side effects.

Half of people with Alopecia Areata may see hair regrowth within a year without treatment, but recovery is unpredictable.

Different types of stem cells exist within individual skin layers, and they can adapt to damage, transplantation, or tumor growth. These cells are regulated by their environment and genetic factors. Tumor growth is driven by expanding, genetically altered cells, not long-lived mutant stem cells. There's evidence of cancer stem cells in skin tumors. Other cells, bacteria, and genetic factors help maintain balance and contribute to disease progression. A method for growing mini organs from single cells has been developed.

No single treatment is consistently effective for alopecia areata, and more research is needed.

The document concludes that hair is complex, with a detailed growth cycle, structure, and clinical importance, affecting various scientific and medical fields.

Alopecia areata is caused by immune system attacks on hair follicles, often triggered by viral infections.

Prolactin affects hair growth and skin conditions, and could be a target for new skin disease treatments.

Animal models have helped understand hair loss from alopecia areata and find new treatments.

Advanced human skin models improve drug development and could replace animal testing.

Children with atopic dermatitis often have sleep problems due to itching and may benefit from melatonin, which helps with sleep and skin symptoms.

People with alopecia areata have more Th17 cells and fewer Treg cells, which may be key to the condition's development.

The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.

Some skin conditions may indicate metabolic syndrome, which could help with early detection and management of related health issues.

RXRα is crucial for proper immune response and links diet to immune function.

Men are more likely to get infectious skin diseases, while women are more prone to autoimmune and pigment-related skin conditions, influenced by biological and environmental factors.

The document concludes that future heart disease research should account for sex-specific differences to improve diagnosis, treatment, and outcomes.

Fat cells are important for tissue repair and stem cell support in various body parts.

Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.

Aging slows wound healing due to weaker cells and immune response.

Diphencyprone treatment increases CD8 lymphocytes in the scalp, which is associated with hair regrowth in alopecia areata patients.